09:50–10:00

OC10

COST-UTILITY OF STRONTIUM RANELATE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN

M. Hiligsmann, O. Bruyère, O. Ethgen, J.-Y. Reginster

10:00–10:10

OC11           

DOSE-DEPENDENT INCREASES IN ENDOGENOUS PARATHYROID HORMONE CONCENTRATIONS AFTER ADMINISTRATION OF A CALCIUM SENSING RECEPTOR ANTAGONIST TO NORMAL VOLUNTEERS: POTENTIAL FOR AN ORAL BONE-FORMING AGENT

D. Ethgen, S. Kumar, L. Fitzpatrick, A. Roshak, J. Phillips, G. Stroup, C. Baidoo, V. Kitchen, C. Matheny

10:10–10:20

OC12

BALLOON KYPHOPLASTY IN PATIENTS WITH ACUTE VERTEBRAL COMPRESSION FRACTURES: IMPACT ON QUALITY OF LIFE AND RISK OF RECURRENT VERTEBRAL FRACTURES

S. Boonen, S. Cummings, R. Eastell, D. Wardlaw

10:50–11:00

OC13

EFFECT OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS ON THE RISK OF FRACTURE

J.B. Richards, A. Papaioannou, J.D. Adachi, L. Joseph, J.C. Prior, H.E. Whitson, David Goltzman

11:00–11:10

OC14

EFFICACY OF ADDING TERIPARATIDE VERSUS SWITCHING TO TERIPARATIDE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS PREVIOUSLY TREATED WITH RALOXIFENE OR ALENDRONATE

F. Cosman, R.A. Wermers, C. Recknor, K.F. Mauck, L. Xie, E.V. Glass, J.H. Krege

11:10–11:20

OC15

HUMAN HIP CARTILAGE VOLUME AND THICKNESS ASSESSED BY NEW QUANTITATIVE MRI TECHNOLOGY: DISCRIMINATION BETWEEN THE ACETABULUM AND THE FEMORAL HEAD

W. Li, F. Abram, Y. Ross, P. Dodin, G. Beaudoin, M.-J. Berthiaume, J.-P. Raynauld, J.-P. Pelletier, J. Martel-Pelletier

11:20–11:30

OC16

EFFICACY OF CONTINUED ALENDRONATE FOR FRACTURES IN WOMEN WITHOUT PREVALENT VERTEBRAL FRACTURE: THE FLEX TRIAL

A.V. Schwartz, D.C. Bauer, J.A. Cauley, K.E. Ensrud, L. Palermo, J.A. West, R.B. Wallace, A.C. Feldstein, M.C. Hochberg, S.R. Cummings

11:30–11:40

OC17

FRACTURE EFFICACY OF MONTHLY IBANDRONATE AND WEEKLY BISPHOSPHONATE THERAPY: A RETROSPECTIVE COHORT STUDY

J.-Y. Reginster, W. Blumentals, C. Barr, S. Silverman, S. Poston

11:40–11:50

OC18

EFFECT OF TREATMENT WITH THE CATHEPSIN-K INHIBITOR, BALICATIB, ON CARTILAGE VOLUME AND BIOCHEMICAL MARKERS OF BONE AND CARTILAGE DEGRADATION IN PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS

D. Manicourt, A. Beaulieu, P. Garnero, C. Peterfy, F. Bouisset, S. Haemmerle, L. Mindeholm

15:30–15:40

OC19           

INCREASED BONE RESORPTION IS ASSOCIATED WITH A HIGH CARDIOVASCULAR RISK IN MEN. THE PROSPECTIVE MINOS STUDY
P. Szulc, P.D. Delmas

15:40–15:50

OC20            

COMPARISON OF THE EFFECTS OF TERIPARATIDE AND ALENDRONATE ON PARAMETERS OF TOTAL HIP STRENGTH AS ASSESSED BY FINITE ELEMENT ANALYSIS: RESULTS FROM THE FORTEO AND ALENDRONATE COMPARISON TRIAL
T.M. Keaveny, P.F. Hoffmann, D.L. Kopperdahl, D.W. Donley, K. Krohn, E.V. Glass, B.H. Mitlak

15:50–16:00

OC21            

ZOLEDRONIC ACID SIGNIFICANTLY REDUCES THE RISK OF VERTEBRAL FRACTURES IN ELDERLY WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: RESULTS FROM HORIZON-PFT
S. Boonen, J.-M. Kaufman, S. Adami, Z. Man, C.-L. Benhamou, G. Bianchi, P. Mesenbrink, J.A. Cauley, E.F. Eriksen, R. Eastell

16:00–16:10

OC22

DENOSUMAB INCREASES BONE MINERAL DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 12 MONTHS
R.K. Dore, E. Hurd, W. Palmer, W. Shergy, N. Lane, S. Cohen, L. Zhou, W. Tsuji, R. Newmark

16:10–16:20

OC23            

PEAK BONE MASS IS ACHIEVED WITHIN 4 YEARS OF PEAK HEIGHT VELOCITY: A LONGITUDINAL ANALYSIS
M.R. Forwood, A.D.G. Baxter-Jones, R.A. Faulkner, R.L. Mirwald, D.A. Bailey

16:20–16:30

OC24

TREATMENT OF OSTEOPOROSIS IN MEN WITH STRONTIUM RANELATE: RESULTS OF A PROSPECTIVE CONTROLLED TRIAL IN 152 PATIENTS
J.D. Ringe, A. Dorst, H. Faber, P. Farahmand

16:30–16:40

OC25           

SEVERITY OF VERTEBRAL FRACTURES IS ASSOCIATED WITH ALTERATIONS OF CORTICAL ARCHITECTURE IN POSTMENOPAUSAL WOMEN, INDEPENDENTLY OF DECREASED BMD. THE OFELY STUDY